Longevity
July 5, 2026
Mark Haden, Birgitta Woods, Tina Woods et al.
Longevity science has increasingly shifted its focus from extending lifespan to improving healthspan, the years lived in good physical, cognitive, and social health. While much research targets biological hallmarks of aging, emerging frameworks emphasize upstream psychosocial drivers such as chronic stress, trauma, social isolation, and health behavior. In parallel, research on psychedelic...
Journal of Psychedelic Studies
July 3, 2025
Mark Haden, Sarah A. Paschall, Birgitta Woods
2 citations
Abstract Psychedelic drug use is experiencing a global resurgence, both in clinical research and community settings. This paper presents a comprehensive public health analysis of the naturalistic use of psychedelics—defined as use outside clinical or research environments. Drawing on a review of 104 peer-reviewed articles, this analysis evaluates the mental, physical, and social outcomes...
Psychedelic medicine (New Rochelle, N.Y.)
September 1, 2024
Michelle St Pierre, Lucas Standing, Yarissa Herman et al.
3 citations
A core component in the provision and receipt of appropriate medical care is trust and communication between patients and physicians. The use of psychedelics for therapeutic purposes (PTPs) has experienced growing attention in the past decade and may be an increasing topic of patient-physician interactions. The stigmatization of psychedelic use may complicate this process. However, patient...
Journal of Psychedelic Studies
December 2, 2023
Mark Haden, Birgitta Woods, Sarah A. Paschall
3 citations
Abstract This analysis of current and historical research and clinical reports observes that the relationship between psychedelics and schizophrenia is complex and there are reports of psychedelics benefiting this population. Specifically, lower doses of psychedelics (mostly LSD) appear to have a potential beneficial impact on the negative symptoms of schizophrenia.
Journal of Studies on Alcohol and Drugs
2020
Mark Haden, Birgitta Woods
31 citations
OBJECTIVE: In academic settings around the world, there is a resurgence of interest in using psychedelic substances for the treatment of addictions, posttraumatic stress disorder, depression, anxiety, and other diagnoses. This case series describes the medical consequences of accidental overdoses in three individuals. METHOD: Case series of information were gathered from interviews, health...
Substance Use & Misuse
January 28, 2017
Mark Haden, John R H Archer, Paul I Dargan et al.
MDMB-CHMICA (methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate) is a synthetic cannabinoid receptor agonist that has been detected in several recreational drug products in Europe since August 2014. This article aims to describe the prevalence of use, availability, and desired and adverse effects of MDMB-CHMICA. Data were collated from published scientific literature,...
Journal of Psychoactive Drugs
2016
Mark Haden, Brian Emerson, Kenneth W. Tupper
The Health Officers Council of British Columbia has proposed post-prohibition regulatory models for currently illegal drugs based on public health principles, and this article continues this work by proposing a model for the regulation and management of psychedelics. This article outlines recent research on psychedelic substances and the key determinants of benefit and harm from their use. It...